Twin Peaks Wealth Advisors LLC Buys 23 Shares of Eli Lilly and Company (NYSE:LLY)

Twin Peaks Wealth Advisors LLC boosted its stake in Eli Lilly and Company (NYSE:LLY) by 3.2% in the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 735 shares of the company’s stock after purchasing an additional 23 shares during the quarter. Twin Peaks Wealth Advisors LLC’s holdings in Eli Lilly and Company were worth $651,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also added to or reduced their stakes in the stock. Azzad Asset Management Inc. ADV grew its stake in Eli Lilly and Company by 2.5% in the first quarter. Azzad Asset Management Inc. ADV now owns 1,814 shares of the company’s stock valued at $1,411,000 after acquiring an additional 45 shares during the period. TCP Asset Management LLC acquired a new position in Eli Lilly and Company in the first quarter valued at about $201,000. Valley National Advisers Inc. grew its stake in Eli Lilly and Company by 2.9% in the first quarter. Valley National Advisers Inc. now owns 5,901 shares of the company’s stock valued at $4,591,000 after acquiring an additional 165 shares during the period. Lake Street Private Wealth LLC grew its stake in Eli Lilly and Company by 5.7% in the first quarter. Lake Street Private Wealth LLC now owns 8,175 shares of the company’s stock valued at $6,360,000 after acquiring an additional 440 shares during the period. Finally, Meadow Creek Wealth Advisors LLC grew its stake in Eli Lilly and Company by 112.4% in the first quarter. Meadow Creek Wealth Advisors LLC now owns 4,161 shares of the company’s stock valued at $3,237,000 after acquiring an additional 2,202 shares during the period. Institutional investors own 82.53% of the company’s stock.

Eli Lilly and Company Stock Performance

LLY opened at $846.90 on Thursday. The company has a debt-to-equity ratio of 1.74, a quick ratio of 0.87 and a current ratio of 1.11. The business’s 50-day simple moving average is $916.20 and its 200 day simple moving average is $865.10. The firm has a market capitalization of $804.90 billion, a PE ratio of 124.73, a PEG ratio of 3.24 and a beta of 0.42. Eli Lilly and Company has a 52-week low of $547.61 and a 52-week high of $972.53.

Eli Lilly and Company (NYSE:LLY) last released its quarterly earnings data on Wednesday, October 30th. The company reported $1.18 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.53 by ($0.35). The business had revenue of $11.44 billion during the quarter, compared to the consensus estimate of $12.09 billion. Eli Lilly and Company had a net margin of 18.86% and a return on equity of 67.52%. Eli Lilly and Company’s quarterly revenue was up 20.4% on a year-over-year basis. During the same quarter in the prior year, the company earned $0.10 EPS. As a group, sell-side analysts expect that Eli Lilly and Company will post 14.05 earnings per share for the current fiscal year.

Eli Lilly and Company Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 10th. Shareholders of record on Friday, November 15th will be paid a $1.30 dividend. The ex-dividend date of this dividend is Friday, November 15th. This represents a $5.20 annualized dividend and a yield of 0.61%. Eli Lilly and Company’s dividend payout ratio is 76.58%.

Wall Street Analyst Weigh In

A number of research firms have issued reports on LLY. Wells Fargo & Company boosted their target price on Eli Lilly and Company from $875.00 to $1,000.00 and gave the company an “overweight” rating in a research note on Friday, August 9th. Truist Financial boosted their target price on Eli Lilly and Company from $1,000.00 to $1,033.00 and gave the company a “buy” rating in a research note on Thursday, October 10th. Deutsche Bank Aktiengesellschaft reaffirmed a “buy” rating and set a $1,025.00 price objective on shares of Eli Lilly and Company in a research report on Thursday, October 3rd. Guggenheim upped their price objective on Eli Lilly and Company from $884.00 to $1,030.00 and gave the stock a “buy” rating in a research report on Friday, August 16th. Finally, Bank of America upped their price objective on Eli Lilly and Company from $1,000.00 to $1,125.00 and gave the stock a “buy” rating in a research report on Friday, August 9th. Three equities research analysts have rated the stock with a hold rating and seventeen have issued a buy rating to the company’s stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $1,013.41.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.